La cadena de opciones muestra datos clave de las opciones de acciones de Oryzon Genomics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Oryzon Genomics..

Oryzon Genomics (OTC:ORYZF) Bolsa, Cadena de Opciones

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics SA

Citigroup analyst James Hardiman initiates coverage on Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Buy rating and announces Price Target of $54.

News

Price Target

Initiation

Analyst Ratings

Citigroup Initiates Coverage On Viking Holdings with Buy Rating, Announces Price Target of $54

Health Care

Contracts

General

MASS

908 Devices And Getinge Announce Their Collaboration To Integrate Getinge's Bioreactors With 908 Devices' MAVEN For Automated Control Of Glucose And Lactate Levels In Cell Cultures

The investment consists of the purchase of 12.5 million shares of Verde's Class A common stock at a purchase price of $4.00 per share. Closing of the investment is anticipated to occur during Q1 2025, subject to satisfaction of customary closing conditions. Upon closing, the investment would represent the second investment by Cottonmouth in Verde over the past two years, for a total investment of $70 million, making Cottonmouth the second largest shareholder of Verde.&nbsp;

Financing

Commodities

Markets

FANG

VGAS

Verde Clean Fuels Entered Into A Stock Purchase Agreement With Cottonmouth Ventures, A Wholly-Owned Subsidiary Of Diamondback Energy, For A $50M Equity Investment

In a bid to attract budget-savvy travelers, Frontier Airlines by Frontier Group Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) has announced the launch of its &#8220;GoWild!&#8221; pass, offering unlimited flights for a year at an introductory price of $299. This offer, which targets spontaneous adventurers, is available to the first 5,000 customers who sign up before the pre-sale ends on December 18.
What Happened: Frontier Airlines is launching a new offer aimed at budget-conscious travelers. The airline&#8217;s &#8220;GoWild!&#8221; pass, priced at $299 annually, provides unlimited flights for a limited time, CNBC <a href="https://www.cnbc.com/2024/12/18/frontier-airlines-all-you-can-fly-pass.html">reported</a> on Thursday 
The &#8220;GoWild!&#8221; pass is designed for spontaneous travelers and those seeking endless adventures, according to Bobby Schroeter, Chief Commercial Officer of Frontier Airlines. The offer is limited to the first 5,000 customers who sign up before the pre-sale ends on Dec. 18 at 11:59 p.m. MST. After this period, the price will rise to $499.
See Also: <a href="https://www.benzinga.com/tech/24/12/42525257/analyst-hikes-teslas-price-target-to-515-musk-expresses-hope-for-stock-to-touch-69042?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Hopes TSLA Stock Will Reach $690 As Analysts Raise Price Target Despite Technical Indicators Flashing Warning Signals</a>
Eligibility for the pass requires users to be at least 18 years old, U.S. residents,&nbsp;and members of Frontier Miles,&nbsp;the airline&#8217;s loyalty program. New customers will be enrolled automatically upon purchase. Pass holders can book flights for a penny, but must cover taxes and fees.
Restrictions include no seat reservations and no carry-on or checked baggage. Domestic flights can be booked a day before departure, while international flights require a 10-day advance booking. The pass is valid from May 1, 2025, to April 30, 2026, excluding holiday and peak travel dates.
Why It Matters: The introduction of the &#8220;GoWild!&#8221; pass by Frontier Airlines comes amid a growing trend among budget airlines to offer unlimited flight passes. In August, European budget airline Wizz Air Holdings launched a similar initiative <a href="https://www.benzinga.com/news/24/08/40387905/this-least-punctual-airline-is-now-offering-a-550-all-you-can-fly-annual-pass-with-unlimited-flights">with a $550 annual pass</a>, allowing unlimited flights to international destinations. 
This pass, available initially at a discounted rate, aimed to attract more customers despite the airline&#8217;s reputation for punctuality issues. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/12/42545829/mark-cuban-expresses-sympathy-for-hawk-tuah-girl-amid-meme-coin-controversy-wasnt-something-she-fully-understood?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Expresses Sympathy For &#8216;Hawk Tuah&#8217; Girl Amid Meme Coin Controversy: &#8216;Wasn&#8217;t Something She Fully Understood&#8217;</a></li>
</ul>
Image via Shutterstock

Travel

ULCC

This Budget US Airline Is Offering A 'GoWild' Pass: Catch Unlimited Flights For A Year At $299

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

Reiteration

PATH

Needham Reiterates Hold on UiPathto Hold

Jefferies analyst Joseph Gallo upgrades SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from Hold to Buy and raises the price target from $27 to $30.

Upgrades

Jefferies Upgrades SentinelOne to Buy, Raises Price Target to $30

BP1001-A downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients. Scientific evidence suggeststhat by downregulating Grb2 expression, BP1001-A&nbsp;could help lower blood glucose level by affecting insulin signaling. Bio-Path conducted preclinical studies that confirmed the effectiveness of BP1001-A in affecting insulin signaling and its potential efficacy as a therapeutic treatment for obese patients who have Type 2 diabetes.&nbsp;&nbsp; The study results showed:
<ul>
<li>BP1001-A reduced Grb2 protein expression in myoblast cells</li>
<li>BP1001-A increased the levels of phosphorylated AKT and phosphorylated FOXO-1 in myoblast and hepatoma cells in the presence of insulin</li>
</ul>
These initial data confirmed that by downregulating Grb2 expression, BP1001-A could enhance insulin-induced metabolic events by affecting the insulin/phosphoinositol-3 kinase (PI3K)/AKT pathway and increase insulin sensitivity.&nbsp;

Biotech

BPTH

Bio-Path Reported That Results From Preclinical Studies Of BP1001-A For Obesity Demonstrated Enhanced Insulin Sensitivity, Confirming BP1001-A As A Potential Treatment For Obesity And Related Metabolic Diseases In Type 2 Diabetes Patients

WIIM

Bio-Path Holdings shares are trading higher after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.

MNMD

MindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024

VRAR

The Glimpse Group shares are trading higher after its subsidiary, Brightline Interactive, announced a six-figure contract with the U.S. Navy for an immersive simulator.

ACET

Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC

The Glimpse Group's Subsidiary Company Brightline Interactive Has Entered Into An Initial Six Figure Dollar Contract With The U.S. Navy For An Immersive Simulator, To Be Delivered In The First Half Of 2025

Jefferies analyst Michael Yee downgrades ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) from Buy to Hold and lowers the price target from $12 to $2.

Downgrades

ALXO

Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2

Fiscal 2025 Expectations
•Organic ASV is expected to grow in the range of $90 million to $140 million during fiscal 2025.
•GAAP revenues are expected to be in the range of $2,285 million to $2,305 million.
•GAAP operating margin is expected to be in the range of 32.5% to 33.5%.
•Adjusted operating margin is expected to be in the range of 36.0% to 37.0%.
•FactSet's annual effective tax rate is expected to be in the range of 17% to 18%.
•GAAP diluted EPS is expected to be in the range of $15.10 to $15.70.
•Adjusted diluted EPS is expected to be in the range of $16.80 to $17.40.

Earnings

Guidance

FactSet Reaffirms FY25 Guidance: Sees Revenues Of $2.285B - $2.305B Vs. $2.301B Est., And Adjusted EPS Of $16.80 - $17.40 Vs. $17.17 Est.

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

VSTM

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

LASE

Laser Photonics Receives Dual Order From Oil Refiner Phillips 66 For CleanTech And MarkStar Laser Systems; No Terms Disclosed

In addition to the Fast Track designation announced today for Waldenstrom's macroglobulinemia, NX-5948 previously received Fast Track designation in January 2024 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) after at least two lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.

NRIX

Nurix Says FDA Granted Fast Track Designation For NX-5948 For Treatment Of Adult Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia After At Least Two Lines Of Therapy

Jefferies analyst Samad Samana upgrades Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) from Hold to Buy and raises the price target from $85 to $100.

Jefferies Upgrades Zoom Communications to Buy, Raises Price Target to $100

Management

LXEO

Lexeo Therapeutics Appoints Dr. Kyle Rasbach As Chief Financial Officer, Effective Immediately.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Uranium Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UROY#NASDAQ">UROY</a>) with a Buy and maintains $7.7 price target.

UROY

HC Wainwright & Co. Reiterates Buy on Uranium Royalty, Maintains $7.7 Price Target

Oryzon Genomics

Comments

Oryzon Genomics

Oryzon Genomics (ORYZF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL